RxSight, Inc. (NASDAQ:RXST - Get Free Report)'s share price rose 0.9% during mid-day trading on Friday . The company traded as high as $47.89 and last traded at $46.80. Approximately 96,595 shares were traded during trading, a decline of 80% from the average daily volume of 485,822 shares. The stock had previously closed at $46.40.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on RXST shares. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. Jefferies Financial Group began coverage on RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price objective for the company. Oppenheimer dropped their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a report on Tuesday, August 6th. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight currently has an average rating of "Buy" and a consensus target price of $61.63.
Read Our Latest Report on RXST
RxSight Price Performance
The firm has a market capitalization of $1.89 billion, a P/E ratio of -56.48 and a beta of 1.19. The firm has a 50-day moving average price of $48.70 and a two-hundred day moving average price of $52.39.
Insider Buying and Selling
In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $142,228.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $1,938,246.48. This trade represents a 6.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jesse Anderson Corley bought 11,111 shares of the firm's stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, with a total value of $504,106.07. Following the completion of the transaction, the director now owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 62,702 shares of company stock valued at $3,059,197 in the last 90 days. Company insiders own 9.36% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its stake in RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of RxSight by 0.7% in the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company's stock worth $1,782,000 after buying an additional 240 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of RxSight by 3.2% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock worth $473,000 after acquiring an additional 242 shares in the last quarter. Quarry LP lifted its position in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company's stock valued at $32,000 after acquiring an additional 288 shares during the last quarter. Finally, RiverPark Advisors LLC boosted its stake in RxSight by 9.6% in the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock valued at $203,000 after acquiring an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company's stock.
About RxSight
(
Get Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
See Also
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
